Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
PROCEPT BioRobotics Corporation - Common Stock
(NQ:
PRCT
)
17.83
+0.67 (+3.90%)
Delayed Quote
Updated: 3:55 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about PROCEPT BioRobotics Corporation - Common Stock
< Previous
1
2
3
4
Next >
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
↗
August 31, 2026
One of J&J's investments stands head-and-shoulders above the rest.
Via
The Motley Fool
Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors?
↗
August 18, 2026
Wood's $498,000 purchase through a trust vehicle expands his beneficial stake to 338,103 shares as the medical robotics firm navigates losses despite $337.3 million in trailing revenue.
Via
The Motley Fool
Topics
Regulatory Compliance
PROCEPT BioRobotics (PRCT) Q2 2026 Earnings Call Transcript
↗
August 11, 2026
HYDROS revenue surged 32% amid legacy account softness and accelerated replacements.
Via
The Motley Fool
Topics
Earnings
World Trade
Procept BioRobotics (NASDAQ:PRCT) Q2 In Line, But Unchanged Guidance Sinks Shares
↗
August 04, 2026
Via
Chartmill
PROCEPT BIOROBOTICS CORP (NASDAQ:PRCT) Q1 Earnings Beat Drives 13% Surge Despite Net Loss
↗
April 29, 2026
Via
Chartmill
Topics
Earnings
PROCEPT BioRobotics Q2 Earnings Call Highlights
↗
August 04, 2026
PROCEPT BioRobotics (NASDAQ:PRCT) reported second-quarter revenue growth of 19% year over year while lowering its full-year U.S. procedure outlook, citing softer activity at legacy AquaBeam accounts....
Via
MarketBeat
Topics
Artificial Intelligence
Earnings
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
↗
May 23, 2026
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.
Via
The Motley Fool
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
↗
May 23, 2026
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.
Via
The Motley Fool
Topics
Artificial Intelligence
PROCEPT BioRobotics Corp (NASDAQ:PRCT) Plummets 27% After Q4 Earnings Miss and Slashed 2026 Guidance
↗
February 25, 2026
Via
Chartmill
Topics
Earnings
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
5 Robotics Stocks to Watch as Physical AI Builds Momentum
↗
May 18, 2026
Via
MarketBeat
Topics
Artificial Intelligence
Procept (PRCT) Q1 2026 Earnings Transcript
↗
April 30, 2026
Procept (PRCT) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Artificial Intelligence
What's going on in today's after hours session
↗
April 29, 2026
Via
Chartmill
Chicago Capital Doubles Down on PROCEPT BioRobotics, Adds $27 Million in Stock
↗
April 24, 2026
This surgical robotics firm develops minimally invasive systems for urologic procedures, targeting hospitals and specialty clinics.
Via
The Motley Fool
PROCEPT BioRobotics (PRCT) Earnings Transcript
↗
April 14, 2026
PROCEPT BioRobotics (PRCT) Earnings Transcript
Via
The Motley Fool
Topics
World Trade
There are notable gap-ups and gap-downs in today's session.
↗
February 26, 2026
Via
Chartmill
Get insights into the top gainers and losers of Thursday's pre-market session.
↗
February 26, 2026
Via
Chartmill
PROCEPT BioRobotics Stock Hits 52-Week Low - Here's Why
↗
February 26, 2026
PROCEPT BioRobotics (NASDAQ: PRCT) shares down on Q4 2025 results and updated revenue guidance. Q1 sales expected at $79-82 million.
Via
Benzinga
PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20
↗
February 26, 2026
Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’.
Via
Stocktwits
Topics
Artificial Intelligence
Top movers in Wednesday's after hours session
↗
February 25, 2026
Via
Chartmill
After a 60% Slide, One Fund Cuts Exposure to This Healthcare Tech Stock by $12.5 Million
↗
February 01, 2026
This healthcare technology firm develops robotic surgical systems for minimally invasive urology procedures targeting BPH treatment.
Via
The Motley Fool
Topics
Regulatory Compliance
3 Underrated Robotics Stocks Poised for Huge Gains
↗
December 15, 2025
Via
MarketBeat
2 Robotics Stocks Riding the Sensor and Medical Boom
↗
October 29, 2025
The robotics infrastructure layer is delivering explosive returns.
Via
The Motley Fool
Is Procept BioRobotics Stock a Buy After Investment Company Chicago Capital Scoops Up Nearly 1 Million Shares?
↗
October 24, 2025
Is Procept BioRobotics Stock a Buy After Investment Company Chicago Capital Scoops Up Nearly 1 Million Shares?
Via
The Motley Fool
Beyond The Numbers: 4 Analysts Discuss PROCEPT BioRobotics Stock
↗
October 15, 2025
Via
Benzinga
Assessing PROCEPT BioRobotics: Insights From 4 Financial Analysts
↗
September 02, 2025
Via
Benzinga
Procept (PRCT) Q2 Revenue Jumps 48%
↗
August 06, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
PROCEPT BioRobotics (PRCT) Earnings Transcript
↗
August 06, 2025
Via
The Motley Fool
Topics
World Trade
PROCEPT BioRobotics Corp. (NASDAQ:PRCT) Reports Q2 2025 Revenue Growth but Misses Profitability Targets, Triggering After-Hours Decline
↗
August 06, 2025
PROCEPT BioRobotics posted strong Q2 2025 revenue growth of 48% YoY but missed profitability estimates, triggering an 8% stock drop. The surgical robotics firm raised full-year guidance but faces...
Via
Chartmill
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
